Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Brings Cervarix To India At Higher Price Than Merck's Gardasil; Will Gynecologists and Pediatricians Help GSK Grab Market Share?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Overcoming a drawn-out registration and approval process, GlaxoSmithKline has finally launched its much awaited vaccine Cerverix in India. Cerverix is used for the prevention of pre-malignant cervical lesions and cervical cancer related to human pappilomavirus (HPV) types 16 and 18
Advertisement

Related Content

India’s Supreme Court To Govt: Respond To Charges Of Safety Breech In Gardasil, Cervarix
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
Advertisement
UsernamePublicRestriction

Register

SC071075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel